Literature DB >> 24630795

Prevalence and persistence of Escherichia coli in the airways of cystic fibrosis patients - an unrecognized CF pathogen?

Petra Barillova1, Veronika Tchesnokova2, Angelika Dübbers3, Peter Küster4, Georg Peters5, Ulrich Dobrindt6, Evgeni V Sokurenko2, Barbara C Kahl7.   

Abstract

Cystic fibrosis (CF) patients suffer from chronic recurrent bacterial airway infections, which eventually lead to reduced life expectancy. Escherichia coli has not been considered as a CF pathogen. A total of 176 patients were observed over 5.6 years on average from 2002 to 2009 in two CF centers in Muenster, Germany. Sputum and throat swab cultures were screened for E. coli. E. coli isolates were analyzed for clinical microbiologic characteristics as well as strain identity, clonal distribution and phenotypic variability. In 45 patients (25.6%) E. coli was cultured at least once, mostly at medium to high bacterial load and primarily from patients less than 5 and older than 8 years. In 19 patients (10.8%) the same E. coli strain was isolated at least 3 times within a period of more than 6 months, with a mean persistence of 29 months. Multi-locus sequence typing revealed a distinctively strong association of CF E. coli with the B2 major clonal group. During persistence, long-term colonizing strains exhibited phenotypic variability known for typical CF pathogens such as surface capsule overproduction and changes in colony size or hemolytic activity. E. coli was occasionally or persistently isolated in a quarter of CF patients, mostly in very young or older patients. The relatively high bacterial load of E. coli colonization, the distinct association with the highly virulent extra-intestinal B2 clonal group and phenotypic variability in the long-term colonizing strains suggests a previously unrecognized clinical significance of E. coli as a CF pathogen.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Airways; Colonization; Cystic fibrosis; Escherichia coli; Pathoadaptation; Persistence

Mesh:

Year:  2014        PMID: 24630795     DOI: 10.1016/j.ijmm.2014.02.008

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  10 in total

1.  Different next generation sequencing platforms produce different microbial profiles and diversity in cystic fibrosis sputum.

Authors:  Andrea Hahn; Amit Sanyal; Geovanny F Perez; Anamaris M Colberg-Poley; Joseph Campos; Mary C Rose; Marcos Pérez-Losada
Journal:  J Microbiol Methods       Date:  2016-09-05       Impact factor: 2.363

2.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

3.  Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.

Authors:  Edith T Zemanick; Brandie D Wagner; Charles E Robertson; Mark J Stevens; Stanley J Szefler; Frank J Accurso; Scott D Sagel; J Kirk Harris
Journal:  Ann Am Thorac Soc       Date:  2015-02

4.  First report of chronic pulmonary infection by KPC-3-producing and colistin-resistant Klebsiella pneumoniae sequence type 258 (ST258) in an adult patient with cystic fibrosis.

Authors:  Emanuele Delfino; Daniele Roberto Giacobbe; Valerio Del Bono; Erika Coppo; Anna Marchese; Graziana Manno; Patrizia Morelli; Laura Minicucci; Claudio Viscoli
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

5.  Extended Bacteria Culture-Based Clustering Identifies a Phenotype Associating Increased Cough and Enterobacterales in Stable Chronic Obstructive Pulmonary Disease.

Authors:  Anaëlle Muggeo; Jeanne-Marie Perotin; Audrey Brisebarre; Sandra Dury; Valérian Dormoy; Claire Launois; Julien Ancel; Pauline Mulette; Christophe de Champs; Gaëtan Deslée; Thomas Guillard
Journal:  Front Microbiol       Date:  2021-12-14       Impact factor: 5.640

6.  Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.

Authors:  Kate Skolnik; Austin Nguyen; Ranjani Somayaji; Christina S Thornton; Barbara Waddell; Michael G Surette; Harvey R Rabin; Michael D Parkins
Journal:  BMC Pulm Med       Date:  2015-12-12       Impact factor: 3.317

7.  Epidemiology of E. coli in Cystic Fibrosis Airways Demonstrates the Capacity for Persistent Infection but Not Patient-Patient Transmission.

Authors:  Conrad Izydorczyk; Barbara Waddell; Brett D Edwards; Jasper Greysson-Wong; Michael G Surette; Ranjani Somayaji; Harvey R Rabin; John M Conly; Deirdre L Church; Michael D Parkins
Journal:  Front Microbiol       Date:  2020-03-20       Impact factor: 5.640

8.  Synthesis and Antimicrobial Activity of Phosphonopeptide Derivatives Incorporating Single and Dual Inhibitors.

Authors:  Keng Tiong Ng; John D Perry; Emma C L Marrs; Sylvain Orenga; Rosaleen J Anderson; Mark Gray
Journal:  Molecules       Date:  2020-03-28       Impact factor: 4.411

9.  Clinical Outcomes Associated With Escherichia coli Infections in Adults With Cystic Fibrosis: A Cohort Study.

Authors:  B D Edwards; R Somayaji; J Greysson-Wong; C Izydorczyk; B Waddell; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  Open Forum Infect Dis       Date:  2019-11-18       Impact factor: 3.835

10.  Inflammation in children with cystic fibrosis: contribution of bacterial production of long-chain fatty acids.

Authors:  Erin Felton; Aszia Burrell; Hollis Chaney; Iman Sami; Anastassios C Koumbourlis; Robert J Freishtat; Keith A Crandall; Andrea Hahn
Journal:  Pediatr Res       Date:  2021-03-02       Impact factor: 3.756

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.